Loading...
Patients with anti–N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis typically present with rapid behavioral changes or psychosis. About 80% substantially improve or fully recover with first-line immunotherapy (IV glucocorticoids, IV immunoglobulin, and/or plasma exchange) and second-line agents (rituximab or cyclophosphamide), but some have prolonged disorders of consciousness characterized by unresponsive wakefulness. To learn more about the clinical course in this latter group, researchers retrospectively analyzed multinational data from 45 patients with anti-NMDAR encephalitis and ≥9 months of disordered consciousness. The median age at onset was 22 years, 84% were female, and 47% had ovarian teratomas; all were admitted to…